Anglia Ruskin University   Report issue

Academic/Hospital Phase 3
Founded: Cambridge United Kingdom (1858)

Organization Overview

First Clinical Trial
2016
NCT02578394
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Anglia Ruskin University

Active Ingredients

Drugs in Phase 3 Trials (3)

anakinra (kineret) (1 trial)

gabapentin (neurontin) (1 trial)

methylprednisolone (medrol) (1 trial)

Drugs in Other Trials (2)

ferrous sulfate (1 trial)

green tea extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gout (Phase 3)

Head and Neck Neoplasms (Phase 3)

Kidney Diseases (Phase 3)

Neuralgia (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5